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Abstract 
BACKGROUND: Small for gestational age (SGA)-born children are a heterogeneous group with few genetic 
causes reported. Genetic alterations in the IGF1 receptor (IGF1R) are found in some SGA children.  
AIM: To investigate whether alterations in IGF1R gene are present in SGA born children. 
PATIENTS AND METHODS: We analysed 64 children born SGA who stayed short (mean -3.25 ± 0.9 SDS) within 
the first 4 years of age, and 36 SGA children who caught up growth (0.20 ± 1.1 SDS). PCR products of all coding 
IGF1R exons were screened by dHPLC followed by direct sequencing of conspicuous fragments to identify small 
nucleotide variants. The presence of IGF1R gene copy number alterations was determined by Multiplex Ligation-
dependent Probe Amplification (MLPA).  
RESULTS: The cohort of short SGA born children revealed a heterozygous, synonymous variant c.3453C > T in 
one patient and a novel heterozygous 3 bp in-frame deletion (c.3234_3236delCAT) resulting in one amino acid 
deletion (p.Ile1078del) in another patient. The first patient had normal serum levels of IGF1. The second patient 
had unusually low IGF1 serum concentrations (-1.57 SD), which contrasts previously published data where IGF1 
levels rarely are found below the age-adjusted mean.  
CONCLUSIONS: IGF1R gene alterations were present in 2 of 64 short SGA children. The patients did not have 
any dysmorphic features or developmental delay. It is remarkable that one of them had significantly decreased 
serum concentrations of IGF1. Growth response to GH treatment in one of the patients was favourable, while the 
second one discontinued the treatment, but with catch-up growth. 
 
 
 
 
 
 
 
 
Introduction 
 
Small for gestational age children (SGA; low 
birth weight and/or birth length) are a heterogeneous 
group both regarding clinical characteristics and the 
aetiology (fetal, maternal, placental, and/or genetic 
factors). Most SGA children normalise their stature by 
2 yr. of age. Nevertheless, approximately 10-15% of 
SGA children do not achieve normal growth and 
height until adolescence and adulthood and remain 
short [1] [2]. In addition to the short stature SGA 
children have a reduced lean body mass, fat mass, 
skin folds, and body mass index (BMI) [3] [4] [5] [6] 
[7], as well as a lower calorie, fat, and carbohydrate 
intake [1] [3]. An impaired IGF1R function may lead to 
disturbed glucose homeostasis [8], which may partly 
explain the increased risk for diabetes in SGA adults.  
IGF-I, the hormone ligand that binds to the 
IGF1R, is fundamental for prenatal and postnatal 
growth and development. Intrauterine and postnatal 
growth retardation, deafness, microcephaly, and 
mental retardation have been reported in homozygous 
deletion or mutation in the IGF1 gene [1] [5]. The 
effects of IGF-I are mediated through the type 1 IGF 
receptor (IGF1R), which is a tyrosine kinase receptor 
encoded by the IGF1R gene [9]. Growth failure and 
microcephaly have been reported in patients with 
IGF1R defects.  
We used dHPLC and Sanger sequencing and 
MLPA to detect small nucleotide variants (SNV) or 
copy number variants (CNV), respectively, to reveal 
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possible genetic alterations in the IGF1R gene as a 
cause of the observed phenotype in SGA children with 
or without catch-up growth.  
 
  
Patients and Methods 
 
SGA was defined as a birth length and/or 
weight < 2 standard deviation scores (SDS) for the 
gestational age. SGA children remaining short at age 
4 (height > 2.00 SDS) were included in the study. All 
children had an uncomplicated perinatal and postnatal 
period. Exclusion criteria included endocrine 
disorders, skeletal abnormalities, chronic diseases 
and chromosomal abnormalities.  
The study protocol was approved by the 
Medical Ethics Committee of the Medical Faculty 
Skopje, Macedonia.  
Birth and growth data before the start of 
treatment were retrieved from records of nurseries, 
and general practitioners. Height and head 
circumference were expressed as SD scores [10]. 
Body mass index was calculated (weight in kg/height 
in meters
2
) and expressed as SD scores for age and 
sex. Bone age was determined according to Greulich 
and Pyle [11]. The dysmorphological examination was 
performed by an experienced clinical geneticist. 
GH pituitary reserve was assessed by L-dopa 
and clonidine GH tests. Serum samples were 
analysed for IGF-1 and IGFBP-3 by either 
chemiluminescent immunoassays (Mediagnost, 
Reutlingen, Germany), or by colourimetric ELISA 
(Mediagnost, Reutlingen, Germany). 
IGF-1 inter- and intra-assay variation 
coefficients were 6.8 and 6.7%, respectively; IGFBP-3 
inter- and intra-assay variation coefficients 6.30 and 
4.51%, respectively. Serum GH was measured by a 
solid-phase, two-site, chemiluminescent 
immunoassay (ARUP, Salt Lake City, Utah, USA). 
Cortisol, testosterone and estrogens were measured 
by colourimetric ELISA (Diagnostic Products 
Corporation, Los Angeles, Calif., USA). 
NA was extracted from peripheral blood 
samples using the QIAamp DNA Blood Mini Kit 
(Qiagen, Hilden, Germany). PCR products of all 
coding exons and adjacent intronic sequences of the 
IGF1R gene were generated and subjected to 
denaturing HPLC (dHPLC) pre-screening (WAVE 
System; Transgenomic, Glasgow, UK). PCR products 
with conspicuous chromatograms were further 
analysed by Sanger dideoxy-sequencing (ABI PRISM 
310 Genetic Analyzer; Thermo Fisher Scientific, 
Waltham, MA). Primer sequences can be obtained 
upon request. Sequences were compared to the 
human reference genome (UCSC, version 19 
(GRCh37)) and annotated according to the GenBank 
reference coding sequence of the IGF1R NM_000875 
and UniProtKB protein reference P08069. Multiplex 
Ligation-dependent Probe Amplification (MLPA) to 
detect copy-number variants (CNV) in the IGF1R 
gene was performed according to the manufacturer’s 
recommendations (SALSA MLPA P217; MRC 
Holland, Amsterdam, The Netherlands).  
 
 
Results 
 
All 64 short SGA children were investigated, 
and mutations in two patients were identified by 
dHPLC and direct sequencing. 
Patient A is a boy who was born 
spontaneously after 37 weeks of gestation and after 
uneventful pregnancy and delivery. He is the second 
child of young, non-consanguineous parents. His 
brother had a normal birth size, and postnatal growth. 
The proband’s birth weight was 1700 g (-3.36 SDS 
score) and birth length 41 cm (-3.66 SDS score). The 
parents’ height was: father 166cm (-0.76 SDS score) 
and of his mother 154.5 cm (-1.9 SDS score), with a 
target height of 166.2 cm (-1.27 SDS score). His 
psychomotor development, sight and hearing were 
normal.  
At 6.3 yr. of age, his height was 101.4 cm (-
3.90 SDS score), weight 13.8 kg (-3.24 SDS weight 
for height), and head circumference was not available. 
L-dopa and clonidine stimulation tests were performed 
at age 5 years with a maximal GH response of 6.31 
ng/ml and 10.8 ng/ml, respectively. At this age, his 
bone age was 4 yr. His IGF-I level was 52.3 ng/ml     
(-1.57 SDS score) and IGFBP-3 level 1.17 mg/liter     
(-1.63 SDS score). Ultrasound of the heart and 
kidneys were uneventful, antibodies for gliadin 
negative. MRI of the hypothalamic and pituitary region 
revealed normal size pituitary and no anomalies. 
Morphologic examination showed no anomalies. He 
attends to a regular primary school. His IQ score was 
89. Since the age of 11.1 years, the GH treatment (37 
µg/kg/day) was given for 18 months. The treatment 
resulted in catch-up growth, and he reached 144.6 cm 
(-0.21 SDS) at 12.7 years when the parents 
interrupted the treatment.  
In patient A a heterozygous synonymous 
nucleotide transition, c.3453C > T (p.I1151 =), was 
found. Position 3435 is located 5 nucleotides 
upstream of the last nucleotide of exon 18. In silico 
analysis using MutationTaster 
(http://www.mutationtaster.org/; accessed April 2018) 
predicts pathogenicity due to a potential splice site 
change. The additional computational analysis 
suggests the introduction of a new exonic splicing 
silencer site while a potentially existing splicing 
enhancer site is broken by the nucleotide substitution 
(Human Splicing Finder 3.1; 
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http://www.umd.be/HSF3/; accessed April 2018). 
Aberrant splicing at the intron 18 splice donor site 
would presumably result in a severely disturbed 
IGF1R function because the affected amino acid 
residue(s) are part of the tyrosine kinase domain.  
 
Figure 1: Genetic analysis of IGF 1R; a novel heterozygous variant 
(synonymous); c.3453C>T; a possible impact on splicing has to be 
verified 
 
The 8.9 old boys was referred for pediatric 
endocrine evaluation because of short stature. He 
was born at 40 wk gestation, after uneventful 
pregnancy and delivery. The parents are young and 
non-consanguineous. His brother and sister had 
normal birth size and normal postnatal growth. His 
birth weight was 2300 g (-2.76 SDS), his birth length 
46 cm (-2.14 SDS), the head circumference at birth 
was not available. The parents’ height was: father 158 
cm (-2.0 SDS score) and of his mother 158.7 cm        
(-1.26 SDS score), with a target height of 165.0 cm     
(-1.38 SDS score). His psychomotor development, 
sight and hearing were normal. At referral, the boy 
had a height of 114.6 cm (-3.08 SDS) and a weight of 
22.2 kg (-1.2 SDS). His head circumference was 49.8 
cm (normal). The Greulich and Pyle male standards 
bone age was 10 years. His sight, hearing and 
development were normal. He had average grades in 
the primary and secondary school. L- Dopa and 
clonidine tests of pituitary GH reserve were 16.4 ng/ml 
and 17.7 ng/ml respectively. Initially, IGF-1 was 468 
ng/ml (reference 237-996) and IGFBP-3 levels were 
not available, but under GH treatment IGF-I was 205 
ng/ml (reference 226–903), while IGF binding protein-
3 (IGFBP)-3 were not available. At the age of 15.41 
years, his height was 138.2 cm (-4.11 SDS), his 
weight 30.3 kg (-2.71 SDS), head circumference 
normal. T4, TSH, cortisol, renal function, hepatic 
analysis were normal. Since the age of 16.25 years (-
3.77 SDS) the GH treatment (37 µg/kg/day) was 
initiated and lasted 3 years. This resulted in a final 
adult height of 160.5 cm (-2.5 SDS) which was within 
the parental target height range.  
In patient B a 3-bp in-frame deletion, 
c.3234_3236delCAT, was identified. The deletion 
probably leads to removal of isoleucine at protein 
position 1078 (p.I1078del) and is predicted to be 
disease-causing (MutationTaster). The affected 
position maps to the tyrosine kinase domain of the 
IGF1R. Isoleucine 1078 is highly conserved among 
species and paralogues (insulin receptor, insulin 
receptor-related receptor) with only isoleucine or 
valine found at this position. Disturbance of the 
receptor’s kinase activity can be assumed but has to 
be shown experimentally. 
 
Figure 2: Genetic analysis of IGF 1R of Patient B; a novel 
heterozygous 3 bp deletion (c.3234_3236delCAT) resulting in a one 
amino acid deletion (p.Ile1078del) 
 
 
 
Discussion 
 
Mutations in the IGF1R gene resulting in IGF1 
resistance underlie some cases of prenatal and 
postnatal growth failure [4]. Interestingly, there were 
three types of phenotypes reported. Some SGA 
children with IGF1R genetic alterations had 
microcephaly and short stature, others had only short 
stature without microcephaly, while some reports 
describe short stature and/or microcephaly and 
impaired glucose tolerance. Also, most reports 
describe elevated circulating levels of IGF1, 
consistent with the expectations when there is a 
receptor defect. It is of note that some patients were 
described with low normal levels of IGF1, as was the 
case in one of our patients with the novel 
heterozygous 3 bp deletion (c.3234_3236delCAT) 
resulting in one amino acid deletion (p.Ile1078del). 
There is one report that describes hypoglycemia 
found in a patient with a heterozygous mutation 
(c.94+1G > A, p.D1105E) affecting the splicing site of 
the IGF1R mRNA [12].  
Several reports describe SGA with growth 
failure: a compound heterozygote for point mutations 
in exon 2 of the IGF1R gene bearing a p.R108Q 
mutation in 1 allele and a p.K115N mutation in the 
second [4]. Short stature and intrauterine growth 
retardation (IUGR) were found to be caused by a 
heterozygous mutation in the IGF1R gene, Arg709 to 
Gln (p.R709Q) [13], while the p.R481Q mutation was 
described in two family members with increased 
serum IGF-I levels and intrauterine and postnatal 
growth retardation [14]. Normal IGF-I, but short 
stature was found in a boy and several family 
members with a 19-nucleotide duplication within exon 
18 of the IGF1R gene and consequently 
haploinsufficiency of IGF1R protein [15]. One of our 
patients had unusually low IGF1 serum concentrations 
(-1.5 SD), which contrasts with previous reports.  
Prenatal and postnatal growth failure was 
found in patients with p.Y387X mutation [16] where 
the proband had high IGF-I levels, while he and his 
two paternal aunts had impaired glucose tolerance. 
SGA was also reported in a novel IGF1R mutation 
(p.Alal 40fsX20) [17], and intrauterine and postnatal 
growth retardation was found in a missense mutation 
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(p.R431L) [18]. Heterozygous nonsense mutations 
affecting the C-terminal region (p.Q1250X, p.W1249X) 
of IGF1R were described in two out of 55 analysed 
Japanese patients with SGA and growth failure [19].  
A heterozygous mutation (p.C1248Y) in the 
IGF1R gene was found in two brothers with prenatal 
and postnatal growth retardation and their father [8]. It 
is of note that OGTT showed progressive impaired 
glucose tolerance, while the father was already 
treated for type 2 diabetes mellitus. In a child with a 
deletion on 15q26.2 intrauterine growth retardation, 
postnatal growth failure, and recurrent hypoglycemia 
there was only a single copy of the IGF1R gene [20]. 
Microcephaly is frequently associated with 
IGF1R genetic alterations. SGA, microcephaly, 
persistent postnatal growth retardation, and elevated 
IGF-I levels were reported in a 15-year-old girl with 
heterozygous deletion of 15q26.2-qter which included 
the IGF1R gene [21]. The p.R59X mutation was 
reported in two half-brothers with primary 
microcephaly, mild mental retardation, and 
intrauterine as well as postnatal growth deficits [4] 
[22]. Microcephaly, pre- and postnatal growth 
retardation were found in patients with heterozygous 
missense mutations in three unrelated patients, de 
novo p.R1256S, de novo p.N359Y and p.Y865C [23]. 
Also the c.1549A > T, the p.Y487F mutation was 
reported in a patient with microcephaly and prenatal 
and postnatal growth impairment [24]. GH treatment 
of a patient with short stature, microcephaly, 
dysmorphic features, developmental delay and a 
terminal deletion of 15q26.2q26.3 containing the 
IGF1R gene in addition to a terminal duplication of the 
4q35.1q35.2 region resulted in a strong growth 
response [25]. It is of note that the GH treatment in 
our patients had mixed effects. The first patient did 
achieve height within the parental target range, while 
the second one discontinued the treatment without 
having a catch-up growth.  
The compound heterozygous mutation 
p.E121K/E234K was reported as the cause of 
intrauterine growth retardation and severe postnatal 
growth failure [26]. The homozygous c.119G > T 
(p.R10L) was shown to be associated with 
dysmorphic features, severe IUGR, and insulin 
resistance [27].  
In conclusion, IGF1R gene alterations are an 
important and relatively frequent cause for SGA. 
Microcephaly with prenatal or postnatal growth failure 
should alert the physician on a possible IGF1R defect. 
Increased IGF-I levels are also a major sign of IGF1R 
defects. It is of note that low normal serum IGF-I 
levels have also been reported, and therefore are not 
an argument not to test the IGF1R gene. A precise 
phenotype-genotype correlation is still lacking. The 
GH treatment in one of the patients did result in a 
height gain into the parental range. However, the 
second patient interrupted the treatment but induced a 
catch-up growth.  
Statement 
 
Written informed consent has been obtained 
from each patient or subject after full explanation of 
the purpose and nature of all procedures used.  
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